![](/img/cover-not-exists.png)
PDB36 LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES
Gaebler J Aledort, Y Samyshkin, ALG Guillermin, A LloydVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72094-0
File:
PDF, 77 KB
english, 2010